Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27800538 | 0.83 | KDM4E (0.47) | TSHRALDH1A1CYP3A4KMT2AKDM4E | |
| SCHEMBL12535895 | 0.81 | LMNA (0.42) | TSHRLMNACYP3A4CYP1A2MAOA | |
| SCHEMBL1806027 | 0.81 | ALDH5A1 (0.59) | ALDH1A1LMNAKDM4EMAPTPKM | |
| SCHEMBL3412166 | 0.79 | GSK3B (0.57) | LMNAKMT2ARAB9ANPC1CYP2C19 | |
| SCHEMBL14388863 | 0.79 | GSK3B (0.55) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL8519584 | 0.79 | NPC1 (0.55) | ALDH1A1CYP3A4CYP1A2MEN1KMT2A | |
| SCHEMBL3415923 | 0.79 | GSK3B (0.57) | TSHRALDH1A1LMNACYP3A4CYP1A2 | |
| SCHEMBL367640 | 0.78 | AKT1 (0.58) | TSHRALDH1A1LMNACYP3A4CYP1A2 | |
| SCHEMBL7112617 | 0.77 | PBRM1 (0.50) | ALDH1A1LMNACYP3A4MEN1KMT2A | |
| SCHEMBL10457452 | 0.77 | MASP2 (0.38) | LMNACYP3A4CYP1A2MAOAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4751304-A | Process for preparing 5,6-dialkoxy-4-alkyl-2(1H)-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-06-14 | — | — | US | claimed |
| EP-0177256-A2 | Process for preparing 5,6-dialkoxy-4-alkyl-2(1h)-quinazolinones | ORTHO PHARMACEUTICAL CORPORATION (US) | 1986-04-09 | — | — | EP | claimed |
| JP-6092912-A | — | — | None | — | — | JP | disclosed |
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
| JP-H0692912-A | PRODUCTION OF DIAMINES | MITSUI TOATSU CHEM INC | 1994-04-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | TSHR 2185/4885ALDH1A1 170/4885LMNA 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.